Sale!

Combiflam (325/400 mg) Tablet

38.07 32.35

Manufactured BySanofi India Ltd.
ContainsParacetamol (325 mg) + Ibuprofen (400 mg)

Message when stock available

Category:
  Ask a Question

Description

Description

Combiflam (325/400 mg) Tablet is a combination medicine used to relieve pain associated with menstrual cycles and arthritis. It is used to relieve mild to moderate pain associated with a headache, toothache, muscle pain, or back pain. It is also used to temporarily relieve fever. This medicine should be used with caution due to the increased risk of liver damage and bleeding complications.

Side effects

Major & minor side effects for Combiflam (325/400 mg) Tablet

  • Nausea or Vomiting
  • Rash
  • Gastric / Mouth Ulcer
  • Bloody and cloudy urine
  • Abnormal blood counts
  • Fatigue
  • Heartburn
  • Abdominal discomfort
  • Constipation
  • Decreased urine output
  • Yellow colored eyes or skin
  • Ringing or buzzing in the ears
  • Loss of appetite
  • Drowsiness
  • Vomiting of blood

Uses of Combiflam (325/400 mg) Tablet

What is it prescribed for?

  • Fever and Pain
    This medicine is used to provide temporary relief from fever and pain without treating the underlying cause.
  • Mild to Moderate pain
    This medicine is used to relieve mild to moderate pain associated with a headache, toothache, muscle pain, or back pain.
  • Menstrual Cramps
    This medicine is used to relieve pain and cramping associated with the menstrual cycle in women.
  • Osteoarthritis
    This medicine is used to treat symptoms such as tender and painful joints associated with Osteoarthritis.
  • Rheumatoid Arthritis
    This medicine is used to treat symptoms such as swelling, pain, and stiffness of joints associated with Rheumatoid Arthritis.
  • Gout
    This medicine is used to relieve the pain and swelling associated with gout.

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

No more offers for this product!

General Inquiries

There are no inquiries yet.